Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review-Reference-Cited by-同舟云学术

Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review

Published:2021-12 Issue:6 Volume:4 Page:914-923
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Van der Eecken Kim,Vanwelkenhuyzen Jan,Deek Matthew P.,Tran Phuoc T.,Warner Evan,Wyatt Alexander W.,Kwan Edmond M.,Verbeke Sofie,Van Dorpe Jo,Fonteyne Valérie,Lumen Nicolaas,De Laere Bram,Ost Piet

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference45 articles.

1. Metastatic hormone-sensitive prostate cancer: a review of the current treatment landscape;Kinsey;Cancer J,2020

2. Comparative analysis of genomic alterations across castration-sensitive and castration-resistant prostate cancer via circulating tumor DNA sequencing;Fan;J Urol,2021

3. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making;Abida;JCO Precis Oncol,2017

4. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer;Kohli;EBioMedicine,2020

5. Genomic correlates of clinical outcome in advanced prostate cancer;Abida;Proc Natl Acad Sci U S A,2019

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatic hormone-naïve prostate cancer: a distinct biological entity;Trends in Cancer;2024-09

2. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients;European Urology Oncology;2024-08

3. PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer;The Prostate;2024-07-17

4. Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?;Cancers;2024-06-26

5. Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance;Frontiers in Endocrinology;2024-06-03